CLINICAL_TRIALS
trial_result
· 2024-08-12
Clinical Trial Update: Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF) [Phase 3]
Summary
Phase 3 study evaluating pamrevlumab for idiopathic pulmonary fibrosis has been terminated; results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Kyntra Bio | Conditions: Idiopathic Pulmonary Fibrosis | Phase 3 | Status: TERMINATED | Results posted: 2024-08-12